A Phase I Study of AC0010 in Patients With Relapsed or Refractory CLL/SLL, MCL, DLBCL and Other Non-Hodgkin B-Cell Lymphoma
Phase of Trial: Phase I
Latest Information Update: 07 Feb 2019
At a glance
- Drugs Abivertinib-maleate (Primary)
- Indications Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Mantle-cell lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions
- Sponsors Hangzhou ACEA Pharmaceutical Research
- 31 Jan 2019 Planned End Date changed from 14 Feb 2020 to 14 Dec 2020.
- 31 Jan 2019 Planned primary completion date changed from 14 Feb 2019 to 14 Dec 2019.
- 29 Sep 2017 Planned number of patients changed from 78 to 184.